Haemophilia management programme: Transformation during COVID-19.

Sait, Haseena; Sajjan, Shruti M; Phadke, Shubha R

Sait, Haseena; Sajjan, Shruti M; Phadke, Shubha R.

Afiliación

Sait H; Department of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Sajjan SM; Department of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Phadke SR; Department of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.

Indian J Med Res ; 155(5&6): 472-477, 2022.

Article en En | MEDLINE | ID: mdl-36124495

Asunto(s)

COVID-19; Hemofilia A; Humanos; Hemofilia A/complicaciones; Hemofilia A/epidemiología; Hemofilia A/tratamiento farmacológico; Estudios Retrospectivos; Calidad de Vida; Pandemias; Control de Enfermedades Transmisibles

Palabras clave

Bleeding disorder; COVID-19; coagulant factor; emicizumab; haemophilia; management

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 / Hemofilia A Tipo de estudio: Observational_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Indian J Med Res Año: 2022 Tipo del documento: Article País de afiliación: India Pais de publicación: India

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google